Trial reportDiabetes, obesity & metabolism2026
Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.
Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsThis Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. MATERIALS AND
methodsParticipants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined. Insulin sensitivity (M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12-week treatment.
resultsOverall baseline means were cDI, 0.3 pmol*m
conclusionThese findings demonstrate that chronic GIP receptor activation in individuals with T2D leads primarily to increased insulin sensitivity, and that combining GIP and GLP-1 receptor agonism can augment both insulin secretion and insulin sensitivity compared to GLP-1 therapy alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.